Navigation Links
Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments

Names Board of Directors

SAN DIEGO, Jan. 31 /PRNewswire/ -- Sonexa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease, announced today that it has raised $30 million in a Series A round of financing. The financing was led by Domain Associates, L.L.C., Scale Venture Partners and Alta Partners. Additional investors included AgeChem Venture Fund, and MC Life Science Ventures. Sonexa also announced the appointment of its Board of Directors. Sonexa founding CEO Eckard Weber, M.D., will serve as Chairman. Weber, a Partner with Domain Associates, is a founding CEO of more than a dozen biopharmaceutical companies. Additional Directors include Kim Puloma Kamdar, Ph.D., of Domain Associates, Lou Bock, a Managing Director with Scale Venture Partners, and Robert Alexander, Ph.D., with Alta Partners. The management team includes president and CMO Sharon Rogers, Ph.D., who played a leading role in developing Aricept, the top-selling Alzheimer's medication.

Proceeds from the financing will be used to fund the licensing and development of a novel drug being tested as a therapeutic to treat Alzheimer's disease. Sonexa has licensed worldwide, exclusive rights (except for Japan and certain Asian countries) to the compound from a Japanese pharmaceutical company. Human trials in the US are scheduled to begin February '08.

About Domain Associates

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.1 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain's three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 190 life-sciences companies. For more information, visit

About Scale Venture Partners

Based in Foster City, California, the ScaleVP team is a long-standing partnership with a consistent, top quartile track record of returns. Scale Venture Partners' insight-driven investment strategy, extensive operating networks and go-to-market expertise help identify and build winning portfolio companies in technology and healthcare markets. The ScaleVP team's proven skill-set and active approach provides entrepreneurs a competitive advantage for growth and category leadership. Representative portfolio companies include Alimera Sciences, Discera, Frontbridge, Glu Mobile, mBlox, Monolithic Power Systems, National Healing, NComputing, Omniture, Orexigen, ScanSafe, Somaxon, Vantage Media, Waterfront Media, Xceive and Zogenix. For more information, visit

About Alta Partners

Alta Partners is a San Francisco based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages over $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage venture opportunities, and has funded over 110 companies in the sector to date. For more information, please visit

Media Contact:

For Sonexa:

Eckard Weber, MD


Sonexa Therapeutics, Inc.


For Scale Venture Partners:

Carol Sacks

Tenor Communications


SOURCE Sonexa Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
Breaking Biology Technology:
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):